Bharat Biotech subsidiary to produce next-generation cancer therapies

Bharat Biotech's subsidiary VeGen Bio has secured a manufacturing agreement to produce advanced cellular and gene therapies, signaling the immunisation company's continued diversification into cutting-edge treatment domains. The partnership represents a strategic step to establish production capabilities for novel therapeutic modalities beyond traditional vaccine manufacturing.

The collaboration focuses on developing cell and gene therapy platforms, with particular emphasis on haematological malignancies. Industry observers note this move positions Bharat Biotech to tap growing demand in India's oncology sector, where access to advanced treatments remains limited.

The companies have targeted 2028 for commercialisation of their lead blood cancer programme, reflecting typical timelines for bringing such specialised therapies through regulatory approval processes in India. This timeline suggests they are currently in advanced development phases.

The expansion underscores Indian pharmaceutical and biotech companies' ambitions to move beyond generic drug manufacturing into higher-value therapeutic segments. Bharat Biotech, already established as a vaccine manufacturer, joins other domestic players investing in cell therapy and gene therapy infrastructure to serve patients regionally.

The specific therapeutic target and manufacturing partner details were not immediately available, but the initiative demonstrates renewed momentum in India's cell and gene therapy ecosystem amid global interest in personalised cancer treatments.